ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 875

Effect of the Dr. Bart Application on Healthcare Use and Clinical Outcomes in People with Osteoarthritis of the Knee And/or Hip in the Netherlands; A Randomized Controlled Trial

Tim Pelle1, Karen Bevers 1, Job van der Palen 2, Frank van den Hoogen 3 and Cornelia van den Ende 1, 1Sint Maartenskliniek Nijmegen, Nijmegen, Netherlands, 2Department of research methodology, Univeristy of Twente, Enschede, Netherlands, 3Sint Maartenskliniek, Nijmegen, Netherlands

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: health behaviors and mHealth, Osteoarthritis, RCT, Self-management

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 10, 2019

Title: 3S092: New Approaches to Old Diseases (875–879)

Session Type: ARP Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Self-management is of paramount importance in non-surgical treatment of knee/hip osteoarthritis (OA). Modern technologies offer the possibility to support self-management 24/7. We developed an e-self-management application (dr. Bart app) for people with knee/hip OA. A central element of the dr. Bart app is that the app proposes a selection of 72 preformulated goals to induce health behaviors based on the ‘tiny habits method’1. The primary objective of this RCT was to evaluate the short term effects (3 & 6 months) of the use of the dr. Bart app (ad libitum), compared to usual care, on the number of secondary health care consultations in people with knee/hip OA in the Netherlands. Secondary objectives were to study the effectiveness on clinical outcomes attributable to dr. Bart app.

Methods: A randomized controlled design involving participants ≥50 years with self-reported knee and/or hip OA, randomly allocated to the dr. Bart app or usual care. Participants were recruited from the community through advertisements in local newspapers and social media campaigns. In Figure 1 the theoretical framework of the dr. Bart app is presented. Participants received online questionnaires at baseline and after 3 and 6 months of follow-up. The primary outcome was the number of consultations in secondary health care due to OA in the knee/hip in the past six months. Secondary outcome measures were self-management behavior, pain, symptoms, functional limitations, physical activity, quality of life, and illness perceptions. Data were analyzed using negative binomial regression or linear mixed models, as appropriate, corrected for baseline, main OA-location (knee or hip), and interaction between treatment group and time.

Results: In total 427 eligible participants were allocated to either the dr. Bart group (n=214) or usual care (n=213). Mean age of the participants was 62.1 (SD 7.3) years, with the majority being female (72%) and having symptoms predominantly in their knee(s) (73%). Response rates for the follow-up questionnaires were 75.4% and 69.3% at 3 and 6 months, respectively. With respect to the number of consultations in secondary health care we found a non-significant incidence rate ratio (1.20 (95% CI: 0.67; 2.19)) between the dr. Bart app group and the usual care group. We found a positive overall treatment effect of the dr. Bart app on symptoms (2.6 (95% CI: 0.4; 4.9)), pain (3.5 (95% CI: 0.9; 6.0)) and, activities of daily living (2.9 (95% CI: 0.2; 5.6)), see Table 1. We found non-significant differences between groups for self-management behavior, physical activity, health-related quality of life and illness perceptions.

Conclusion: The dr. Bart app did not reduce the number of secondary health care consultations compared to usual care. However, we found positive effects attributable to the dr. Bart app on pain, symptoms, activities of daily living and functioning in sport and recreation in people with knee/hip OA, suggesting that the dr. Bart app has potential to positively influence health in people with knee/hip OA.
Reference:

  1. Fogg GJ: A behavior model for persuasive design. In: Proceedings of the 4th international Conference on Persuasive Technology: 2009: ACM; 2009: 40.

Figure 1. Theoretical framework of the dr. Bart app.

Table 1. Overall treatment effect and treatment effects at 3 and 6 months of the dr. Bart app.
* Indicates p-value < 0.05
† Reported as incidence rate ratio
§Adjusted for baseline value, treatment group and main OA-location -knee/hip-
∞ Adjusted for time, and interaction between treatment group and time
Abbreviations: KOOS; Knee Injury and Osteoarthritis Outcome Score; HOOS; Hip Disability and Osteoarthritis Outcome Score.


Disclosure: T. Pelle, None; K. Bevers, None; J. van der Palen, None; F. van den Hoogen, AbbVie, 5, Actelion, 2, Amgen, 8, Biogen, 5, BMS, 2, Boehringer Ingelheim, 5, Celgene, 5, Celltrion Healthcare, 5, 8, Corbus, 8, Eli Lily, 2, Janssen, 8, Mundipharma, 5, Novartis, 5, Pfizer, 2, Roche, 8, Sandoz, 8, Sanofi Genzyme, 5; C. van den Ende, None.

To cite this abstract in AMA style:

Pelle T, Bevers K, van der Palen J, van den Hoogen F, van den Ende C. Effect of the Dr. Bart Application on Healthcare Use and Clinical Outcomes in People with Osteoarthritis of the Knee And/or Hip in the Netherlands; A Randomized Controlled Trial [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/effect-of-the-dr-bart-application-on-healthcare-use-and-clinical-outcomes-in-people-with-osteoarthritis-of-the-knee-and-or-hip-in-the-netherlands-a-randomized-controlled-trial/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effect-of-the-dr-bart-application-on-healthcare-use-and-clinical-outcomes-in-people-with-osteoarthritis-of-the-knee-and-or-hip-in-the-netherlands-a-randomized-controlled-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology